A case-control study on immunologic markers of patients with vitiligo

Area of Science:

• Dermatology
• Immunology
• Biochemistry

Background:

• Vitiligo is a depigmentation disorder affecting 0.5-2% globally, often linked to autoimmune conditions.
• Its pathogenesis involves genetic, environmental, and biochemical factors.
• Identifying reliable biomarkers is crucial for disease management.

Purpose of the Study:

• To quantify specific cytokines (IL-17, IL-22, IL-23) in vitiligo patients' blood sera.
• To determine the most effective biomarker for vitiligo diagnosis and activity assessment.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure IL-17, IL-22, and IL-23 levels.
• Study included 50 vitiligo patients and 38 controls, assessing disease type, body surface area (BSA), and progression.
• Patient phototype and medical history, including coexisting conditions like hypothyroidism, were recorded.

Main Results:

• Elevated concentrations of IL-22 and IL-23 were observed in vitiligo patients compared to controls.
• IL-22 levels showed a significant increase with disease severity, being highest in patients with BSA ≥ 10%.
• Hypothyroidism was more prevalent in vitiligo patients (11 vs 2 controls).

Conclusions:

• IL-22 and IL-23 show potential as biomarkers for vitiligo.
• IL-22 is identified as a superior marker for active universal vitiligo, directly correlating with lesion extent.
• Further research can validate IL-22 for clinical application in vitiligo management.